<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="6.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Akhtar, Nasim</style></author><author><style face="normal" font="default" size="100%">Padilla, Marcia L</style></author><author><style face="normal" font="default" size="100%">Dickerson, Erin B</style></author><author><style face="normal" font="default" size="100%">Steinberg, Howard</style></author><author><style face="normal" font="default" size="100%">Breen, Matthew</style></author><author><style face="normal" font="default" size="100%">Auerbach, Robert</style></author><author><style face="normal" font="default" size="100%">Helfand, S C</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model.</style></title><secondary-title><style face="normal" font="default" size="100%">Neoplasia (New York, N.Y.)</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Neoplasia</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Adhesion</style></keyword><keyword><style  face="normal" font="default" size="100%">Cell Division</style></keyword><keyword><style  face="normal" font="default" size="100%">Corneal Neovascularization</style></keyword><keyword><style  face="normal" font="default" size="100%">Cytokines</style></keyword><keyword><style  face="normal" font="default" size="100%">Dogs</style></keyword><keyword><style  face="normal" font="default" size="100%">Endothelium, Vascular</style></keyword><keyword><style  face="normal" font="default" size="100%">Flow Cytometry</style></keyword><keyword><style  face="normal" font="default" size="100%">Growth Substances</style></keyword><keyword><style  face="normal" font="default" size="100%">Hemangiosarcoma</style></keyword><keyword><style  face="normal" font="default" size="100%">Interleukin-12</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice, Inbred BALB C</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice, Inbred NOD</style></keyword><keyword><style  face="normal" font="default" size="100%">Mice, SCID</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasm Transplantation</style></keyword><keyword><style  face="normal" font="default" size="100%">Neovascularization, Pathologic</style></keyword><keyword><style  face="normal" font="default" size="100%">Reverse Transcriptase Polymerase Chain Reaction</style></keyword><keyword><style  face="normal" font="default" size="100%">Soft Tissue Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Transplantation, Heterologous</style></keyword><keyword><style  face="normal" font="default" size="100%">Tumor Cells, Cultured</style></keyword><keyword><style  face="normal" font="default" size="100%">Tumor Markers, Biological</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2004</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2004 Mar-Apr</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">6</style></volume><pages><style face="normal" font="default" size="100%">106-16</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">We established a canine hemangiosarcoma cell line derived from malignant endothelial cells comprising a spontaneous tumor in a dog to provide a renewable source of endothelial cells for studies of angiogenesis in malignancy. Pieces of the hemangiosarcoma biopsy were engrafted subcutaneously in a bg/nu/XID mouse allowing the tumor cells to expand in vivo. A cell line, SB-HSA, was derived from the xenograft. SB-HSA cells expressed vascular endothelial growth factor (VEGF) receptors 1 and 2, CD31, CD146, and alpha(v)beta(3) integrin, and produced several growth factors and cytokines, including VEGF, basic fibroblast growth factor, and interleukin (IL)-8 that are stimulatory to endothelial cell growth. These results indicated that the cells recapitulated features of mitotically activated endothelia. In vivo, SB-HSA cells stimulated robust angiogenic responses in mice and formed tumor masses composed of aberrant vascular channels in immunocompromised mice providing novel opportunities for investigating the effectiveness of antiangiogenic agents. Using this model, we determined that IL-12, a cytokine with both immunostimulatory and antiangiogenic effects, suppressed angiogenesis induced by, and tumor growth of, SB-HSA cells. The endothelial cell model we have described offers unique opportunities to pursue further investigations with IL-12, as well as other antiangiogenic approaches in cancer therapy.</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/15140399?dopt=Abstract</style></custom1></record></records></xml>